LAWRENCE FONG, M.D.

Lawrence Fong, M.D. is Senior Vice President, the inaugural Bezos Family Distinguished Scholar, and director of the Translational Sciences and Therapeutics Division at Fred Hutch Cancer Center. He is also a Professor of Medicine in the Department of Medicine, Division of Hematology/Oncology in the University of Washington. He received his B.A. from Columbia University and his M.D. from Stanford University. As a physician-scientist, Dr. Fong has been involved in both pre-clinical and clinical studies of multiple cancer immunotherapies including immune checkpoint inhibitors and the cancer vaccine sipuleucel-T that are now FDA-approved. He has built and led immunotherapy-focused phase 1 clinical programs and has been involved with >100 first in human clinical trials. His NIH-funded laboratory has defined multiple immunologic mechanisms that underlie response and resistance to immunotherapies that could enable novel treatments.  His work has been published in Nature, Cell, Science, and the New England Journal of Medicine. He is a founding senior editor for the Journal of Immunotherapy of Cancer and for Cancer Immunology Research. He is a recipient of the NIH Outstanding Investigator Award, an elected board member of the Society for Immunotherapy of Cancer (SITC), and an elected member of the American Society for Clinical Investigation; and has served on the National Cancer Institute Board of Scientific Counselors and Investigational Drug Steering Committee.